4D Molecular Therapeutics reports clinical, financial and governance developments for a late-stage biotechnology company developing disease-targeted gene therapy product candidates. Its recurring updates center on 4D-150 for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema, and on clinical programs such as 4FRONT, PRISM and SPECTRA.
Company news also covers quarterly and annual financial results, cash runway commentary, collaboration and license revenue tied to Otsuka, investor conference participation, board and leadership changes, and employment inducement equity grants. The company states that its product candidates remain in clinical or preclinical development and have not been approved for marketing by the FDA or other regulatory authorities.
4D Molecular Therapeutics announced the dosing of the first patient in its Phase 1/2 clinical trial of 4D-310, aimed at treating Fabry disease, a condition with significant unmet medical needs. The trial will evaluate safety, tolerability, and activity of the therapy, with enrollment set for up to 18 patients. 4D-310 employs a novel dual mechanism targeting AGA enzyme activity in blood and affected tissues, addressing limitations of current enzyme replacement therapies. This advancement highlights the company's commitment to innovative gene therapies.
4D Molecular Therapeutics has successfully closed its initial public offering, selling 9,660,000 shares at $23.00 each, totaling approximately $222 million in gross proceeds. The offering included 1,260,000 shares from the underwriters' option. Shares began trading on the Nasdaq under the ticker symbol FDMT. The company specializes in gene therapy using directed evolution and is currently engaged in three clinical trials targeting ophthalmology, cardiology, and pulmonology, aiming to enhance delivery efficacy while minimizing immunogenicity.